ClinicalTrials.gg

Program

tirabrutinib

Also written as “Tirabrutinib” and “ONO-4059”.

Its studies are mostly in Leukemia, Lymphocytic, Chronic, B-Cell · Pemphigus · Chronic Urticaria · Lymphoma, Non-Hodgkin · Sjogren's Syndrome, led by 2 companies.

Furthest: phase 3, since Nov 16, 201613 company-led studies, 4 open or runningNext primary completion: Sep 30, 2027 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Gilead Sciences80 open or runningphase 2since Nov 16, 2016Jul 6, 2012none ahead
Ono Pharmaceutical54 open or runningphase 3since Nov 7, 2024Jun 16, 2021Sep 30, 2027phase 3 · NCT06696716

Also a collaborator on its studies: Lakefront Biotherapeutics NV.

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 6, 2012First study: phase 1 study in Lymphoma, Non-HodgkinNew to Gilead SciencesGilead Sciences · NCT01659255 · 90 enrolled · France, United Kingdom
  2. May 27, 20152 phase 1 studiesGilead Sciences · NCT02457598, NCT02457559
  3. Dec 3, 2015Phase 1 study in Arthritis, RheumatoidGilead Sciences · NCT02626026 · 42 enrolled · United States
  4. Nov 16, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02968563 · 35 enrolled · Germany
  5. Dec 2, 2016Phase 2 study in Leukemia, Lymphocytic, Chronic, B-CellGilead Sciences · NCT02983617 · 36 enrolled · Germany
  6. Mar 31, 2017Phase 2 study in Sjogren's SyndromeGilead Sciences · NCT03100942 · 152 enrolled · United States, Poland, Spain and more
  7. Mar 30, 2021Phase 2 study in Chronic UrticariaGilead Sciences · NCT04827589
  8. Jun 16, 2021Ono Pharmaceutical's first study: phase 2 study in Refractory Primary Central Nervous System LymphomaNew to Ono PharmaceuticalOno Pharmaceutical · NCT04947319 · 119 enrolled · United States
  9. Aug 2, 2024Phase 1 study in Primary Central Nervous System LymphomaOno Pharmaceutical · NCT06541665 · 20 enrolled · Japan
  10. Nov 7, 2024Phase 3 study in PemphigusOno Pharmaceutical · NCT06696716 · 34 enrolled · Japan
  11. Jul 29, 2025Phase 3 study in RecurrenceOno Pharmaceutical · NCT07104032 · 132 planned · United States, Australia, Brazil and more
  12. Aug 31, 2025Phase 1 study in Primary Central Nervous System Lymphoma (PCNSL)Ono Pharmaceutical · NCT07198087 · 40 enrolled · United States

Ahead

  1. Sep 30, 2027Primary completion: phase 3 study in PemphigusOno Pharmaceutical · NCT06696716
  2. Dec 2027Primary completion: phase 3 study in RecurrenceOno Pharmaceutical · NCT07104032
  3. Apr 28, 2028Primary completion: phase 1 study in Primary Central Nervous System LymphomaOno Pharmaceutical · NCT06541665

TargetBeta

BTK →read by rule
“An orally available formulation containing an inhibitor of Bruton agammaglobulinemia tyrosine kinase (BTK), ”NCIt, by rule
“Tyrosine-protein kinase BTK inhibitor”ChEMBL 37, by rule

Other programs on BTK

ProgramCompanyFurthest phaseStudies
ibrutinibruleJohnson & Johnsonphase 478
acalabrutinibruleAstraZenecaphase 455
zanubrutinibruleBeOne Medicinesphase 435
pirtobrutinibruleEli Lillyphase 430
ritlecitinibrulePfizerphase 342
orelabrutinibruleInnoCare Pharmaphase 327
rilzabrutinibruleSanofiphase 323
evobrutinibruleMerck KGaA, Darmstadt, Germanyphase 320
fenebrutinibHoffmann-La Rochephase 318
nemtabrutinibMerckphase 316
rocbrutinibruleLupeng Pharmaceuticalphase 315
birelentinibruleDizal Pharmaceuticalsphase 312

Studies

All 13 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07198087Primary Central Nervous System Lymphoma (PCNSL) · United States1CompletedOno PharmaceuticalApr 9, 202640
NCT07104032Recurrence · United States, Australia, Brazil and more3RecruitingOno PharmaceuticalDec 2027132
NCT06696716Pemphigus · Japan3Active, not recruitingOno PharmaceuticalSep 30, 202734
NCT06541665Primary Central Nervous System Lymphoma · Japan1Active, not recruitingOno PharmaceuticalApr 28, 202820
NCT04947319Refractory Primary Central Nervous System Lymphoma · United States2Active, not recruitingOno PharmaceuticalJan 27, 2026119
NCT04827589Chronic Urticaria2WithdrawnGilead SciencesApr 20220
NCT03100942Sjogren's Syndrome · United States, Poland, Spain and more2CompletedGilead SciencesJan 10, 2019152
NCT02983617Leukemia, Lymphocytic, Chronic, B-Cell · Germany2CompletedGilead SciencesFeb 20, 201936
NCT02968563Leukemia, Lymphocytic, Chronic, B-Cell · Germany2CompletedGilead SciencesJun 17, 201935
NCT02626026Arthritis, Rheumatoid · United States1CompletedGilead SciencesSep 1, 201642
NCT02457598B-cell Malignancies · United States, France, United Kingdom1TerminatedGilead SciencesSep 25, 2024203
NCT02457559Recurrence · France, United Kingdom1CompletedGilead SciencesDec 30, 202029
NCT01659255Lymphoma, Non-Hodgkin · France, United Kingdom1CompletedGilead SciencesFeb 23, 201590

How it is read

Names in the registry

  • “Tirabrutinib”, 13 entries
  • “ONO-4059”, 2 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.